Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 397-406

  Yoshinaga, Tomokazu ^a   Kobayashi, Masanori ^a   Seki, Takahiro ^a   Miki, Shigeru ^a   Wakasa Morimoto, Chiaki ^a   Suyama Kagitani, Akemi ^a   Kawauchi Miki, Shinobu ^a   Taishi, Teruhiko ^a   Kawasuji, Takashi ^a   Johns, Brian A ^b   Underwood, Mark R ^b   Garvey, Edward P ^b   Sato, Akihiko ^a   Fujiwara, Tamio ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CABOTEGRAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; INTEGRASE; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; LAMIVUDINE; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; PYRIDONE DERIVATIVE; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SELECTIVITY; EC50; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR CLONING; SITE DIRECTED MUTAGENESIS; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; VIROLOGY;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIDONES; QUINOLONES; RALTEGRAVIR POTASSIUM; VIRUS REPLICATION;

EID: 84920189964     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03909-14     Document Type: Article

References (41)

1. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46:125-133. http://dx.doi.org/10.1097/QAI.0b013e318157131c.
2. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43:509-515. http://dx.doi.org/10.1097 /QAI.0b013e31802b4956.
3. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatmentexperienced patients. J Acquir Immune Defic Syndr 43:1-5. http://dx.doi .org/10.1097/01.qai.0000233308.82860.2f.
4. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:2439-2448. http://dx.doi.org/10.1016/S0140-6736(12)60917-9. (Erratum, 380:730.)
5. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP. 2012. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379: 2429-2438. http://dx.doi.org /10.1016/S0140-6736(12)60918-0.
6. Arribas JR, Eron J. 2013. Advances in antiretroviral therapy. Curr Opin HIV AIDS 8:341-349. http://dx.doi.org/10.1097/COH.0b013e328361fabd.
7. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354. http://dx.doi.org/10.1021/bi800791q.
8. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. 2013. Update of the drug resistance mutations in HIV-1. Top Antivir Med 21:6-14.
9. Geretti AM, Armenia D, Ceccherini-Silbestein F. 2012. Emerging patterns and implications ofHIV-1integrase inhibitor resistance. CurrOpinInfect Dis 25:677-686. http://dx.doi.org/10.1097/QCO.0b013e32835a1de7.
10. Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C. 2012. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 56: 2873-2878. http://dx.doi.org/10.1128/AAC.06170-11.
11. Menéndez-Arias L. 2013. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98:93-120. http://dx.doi.org/10.1016/j.antiviral.2013.01.007.
12. Huang W, Frantzell A, Fransen S, Petropoulos CJ. 2013. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 57:4105-4113. http://dx.doi.org/10.1128 /AAC.00204-13.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, F-4, Table 5a. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/lvguidelines /adultandadolescentgl.pdf.
14. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Jhons BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretoroviral properties of S/GSK1349572, a nextgeneration HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
15. Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R, Fuji M, Tanimoto N, Jeffrey J, Foster SA, Yoshinaga T, Seki T, Kobayashi M, Sato A, Johnson MN, Garvey EP, Fujiwara T. 2013. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK 1349572) and (S/GSK1265744). J Med Chem 56:5901-5916. http://dx.doi .org/10.1021/jm400645w.
16. Spreen W, Min S, Ford SL, Chen S, Lou Y, Bomar M, St Clair M, Piscitelli S, Fujiwara T. 2013. Pharmacokinetics, safety, and mono-therapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14:192-203. http://dx.doi.org/10.1310/hct1405 -192.
17. Spreen WR, Margolis DA, Pottage JC, Jr. 2013. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 8:565-571. http://dx.doi.org/10.1097/COH.0000000000000002.
18. Underwood M, St Clair M, Johns BA, et al. 2010. S/GSK1265744: a next generation integrase inhibitor (INI) with activity against raltegravirresistant clinical isolates, abstr MOAA0103. Twenty-Eighth Int AIDS Conf, Vienna, Austria.
19. Spreen W, Williams P, Margolis D, Ford S, Crauwels H, Lou Y, Gould E, Stevens M, Piscitelli S. 2013. First study of repeat dose coadministration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety and tolerability in healthy adults, abstr WEAB0103. Seventh IAS Conf HIV Pathog Treat Prev, Kuala Lumpur, Malaysia. http://www.ias2013.org/.
20. Plosker GL. 2013. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs 73:279-291. http://dx .doi.org/10.1007/s40265-013-0024-4.
21. Daluge SM, Purifoy DJ, Savina PM, St Clair M, Parry NR, Dev IK, Novak P, Ayers KM, Reardon JE, Roberts GB, et al. 1994. 5-Chloro-2=,3=-dideoxy-3=-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother 38:1590-1603. http://dx.doi.org /10.1128/AAC.38.7.1590.
22. Harada S, Koyanagi Y, Yamamoto N. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566. http://dx.doi.org/10.1126/science.2992081.
23. Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, Uchiyama T, Adachi A, Hayami M, Fujiwara T, Yoshie O. 1999. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264:237-243. http://dx.doi.org/10.1006/viro.1999.0006.
24. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
25. Jarmy G, Heinkelein M, Weissbrich B, Jassoy C, Rethwilm A. 2001. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol 64:223-231. http://dx.doi.org/10.1002/jmv.1040.
26. Boros EE, Johns BA, Garvey EP, Koble CS, Miller WH. 2006. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy [1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg Med Chem Lett 16:5668-5672. http://dx.doi.org/10.1016/j.bmcl.2006.08.007.
27. Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T. 2008. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 52:901-908. http://dx.doi.org/10.1128/AAC .01218-07.
28. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T. 2008. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 80:213-222. http://dx.doi.org/10.1016/j .antiviral.2008.06.012.
29. Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ. 2003. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob Agents Chemother 47: 1468-1471. http://dx.doi.org/10.1128/AAC.47.4.1468-1471.2003.
30. Tukey JW, Ciminera JL, Heyse JF. 1985. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301. http: //dx.doi.org/10.2307/2530666.
31. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181-205. http://dx.doi.org /10.1016/0166-3542(90)90001-N.
32. Baert L, van 't Klooster G, Dries W, et al. 2009. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 72:502-508. http: //dx.doi.org/10.1016/j.ejpb.2009.03.006.
33. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, inte-grase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
34. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650. http://dx.doi.org/10.1126/science.287 .5453.646.
35. Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M, Nichols G. 2013. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 57:1379-1384. http://dx.doi.org/10.1128/AAC.01791-12.
36. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82:764-774. http://dx.doi.org/10.1128/JVI .01534-07.
37. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S. 2013. Dolutegravir in antiretro-viral-naive adults with HIV-1: 96-week results from a randomized doseranging study. AIDS 27:1771-1778. http://dx.doi.org/10.1097/QAD.0b01 3e3283612419.
38. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
39. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735-743. http://dx.doi.org/10.1016/S0140-6736(12)61853-4.
40. Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the sec-ond-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
41. Bar-Magen Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 84:9210-9216. http://dx.doi.org/10 .1128/JVI.01164-10.